News from NORD

FDA Launches Expanded Access Navigator


 

Patients with serious or immediately life-threatening diseases or conditions who have no comparable or satisfactory alternative therapy and who seek access to potentially life-saving investigational drugs can use the FDA’s new Expanded Access Navigator to guide them through the process. The Navigator was a team effort led by the Reagan-Udall Foundation in collaboration with patient advocacy groups, the pharmaceutical industry, the FDA, and others in the Federal government.

Recommended Reading

Supportive care alone linked to worse outcomes in mucocutaneous reactions
MDedge Dermatology
Many aspects to caring for epidermolysis bullosa patients
MDedge Dermatology
Bone marrow transplantation for epidermolysis bullosa continues to evolve
MDedge Dermatology
Adalimumab for Hidradenitis Suppurativa
MDedge Dermatology
Precise cause of pityriasis rosea remains elusive
MDedge Dermatology
Care of infants with ichthyosis requires ‘all hands on deck’
MDedge Dermatology
Screening MRI misses Sturge-Weber in babies with port-wine stain
MDedge Dermatology
Preview Agenda for NORD’s 2017 Rare Diseases and Orphan Products
MDedge Dermatology
FDA Commissioner to Present Keynote Address at NORD Summit
MDedge Dermatology
Examining the Role of Caregivers at NINR Caregiving Summit
MDedge Dermatology